References
- Million Women Study Collaborators. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet Online April 19, 2007
- Prat H J. Pathology of the Ovary. Saunders, Philadelphia 2004
- Million Women Study Collaborators. Breast cancer and hormone therapy in the Million Women Study. Lancet 2003; 362: 419–427
- Kaufman D W, Kelly J P, Welch W R, et al. Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol 1989; 130: 1142–1151
- Weiss N S, Lyon J L, Krishnamurthy S, et al. Non-contraceptive estrogen use and the occurrence of ovarian cancer. JNCI 1982; 115: 714–719
- Cramer D W, Hutchison G B, Welch W R, et al. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. JNCI 1983; 71: 711–716
- Hartge P, Hoover R, McGowan L, et al. Ovarian cancer: incidence and case-control study. Am J Epidemiol 1988; 127: 990–998
- Shapiro S. Commentary: Bias in the evaluation of low-magnitude associations: an empirical perspective. Am J Epidemiol 2000; 151: 939–945
References
- Million Women Study Collaborators. Ovarian cancer and hormone-replacement therapy in the Million Women Study. Lancet 2007; 369: 1703–1710
- Shapiro S. False alarm: postmenopausal hormone therapy and ovarian cancer. Climacteric 2007; 10: 466–9
- Million Women Study Collaborators. Patterns of use of hormone replacement therapy in one million women in Britain, 1996–2000. Br J Obstet Gynaecol 2002; 109: 1319–1330
- Watson J, Wise L, Green J. Prescribing hormones for the menopause, tibolone and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 2007, DOI 10.1007/s00228-007-0320-6
- Ravdin P M, Cronin K A, Howlander N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007; 356: 1670–1674